Lepu Biopharma Company Description

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of first-in class and best-in-class drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally.

The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma.

It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive.

In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin’s lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors.

Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors.

The company was incorporated in 2018 and is headquartered in Shanghai, China.

Lepu Biopharma Co., Ltd.

Country	China
Founded	2018
Industry	Biotechnology
Sector	Healthcare
Employees	498
CEO	Ziye Sui

Contact Details

Address: No. 651, Lianheng Road Shanghai, 201612 China
Phone	86 21 6768 0899
Website	lepubiopharma.com

Stock Details

Ticker Symbol	2157
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	CNE100004SM4
SIC Code	2836

Key Executives

Name	Position
Dr. Ziye Sui M.D., Ph.D.	Chief Executive Officer and Director
Dr. Zhongjie Pu	Executive Chairman
Yunyi Li	Chief Financial Officer and Board Secretary
Lixuan Zhao	Supervisor and Investor Relations Director
Siu Kuen Lai FCIS, FCS	Joint Company Secretary